Antithrombotic therapy for patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention: A review

Keyphrases

• Antithrombotic Therapy 100%
• Percutaneous Coronary Intervention 100%
• Paroxysmal Atrial Fibrillation 100%
• Aspirin 66%
• Dual Antiplatelet Therapy 66%
• Atrial Fibrillation 66%
• Risk Factors 33%
• Major Bleeding 33%
• Antiplatelet Therapy 33%
• Systemic Embolism 33%
• Warfarin 33%
• Ischemic Stroke 33%
• Stent Thrombosis 33%
• Bleeding Complications 33%
• Novel Oral Anticoagulants 33%
• Oral Anticoagulant Therapy 33%
• Rivaroxaban 33%
• Recurrent Ischemic Events 33%
• Thienopyridines 33%
• Thromboembolism 33%
• Drug-eluting Stent 33%
• Apixaban 33%
• Dabigatran 33%
• Edoxaban 33%
• Antiplatelet Agents 33%
• Factor Xa 33%
• Prasugrel 33%
• Ticagrelor 33%
• Factor IIa 33%
• Alternative Regimens 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Atrial Fibrillation 100%
• Antithrombotic Therapy 100%
• Antiplatelet 100%
• Acetylsalicylic Acid 66%
• Anticoagulant Agent 33%
• Bleeding 33%
• Warfarin 33%
• Brain Ischemia 33%
• Stent Thrombosis 33%
• Receptor 33%
• Rivaroxaban 33%
• Anticoagulation Therapy 33%
• Thienopyridine 33%
• Thromboembolism 33%
• Apixaban 33%
• Edoxaban 33%
• Dabigatran 33%
• Antithrombocytic Agent 33%
• Blood Clotting Factor 10a 33%
• Prasugrel 33%
• Ticagrelor 33%
• Embolism 33%